Framing the Evidence: L-Arginine and Vitamin C Beyond Pulmonary Rehabilitation

A new multicenter randomized trial in Thorax provides an interesting signal that may extend beyond COPD.

In 98 patients with advanced COPD, chronic respiratory failure, and long-term oxygen therapy, adding oral L-arginine plus liposomal vitamin C to a 28-day pulmonary rehabilitation program produced a greater reduction in fatigue than placebo. The between-group difference in Fatigue Severity Scale score was 0.90 points, exceeding the prespecified clinically meaningful threshold of 0.6. However, objective functional outcomes, including 6-minute walking distance, handgrip strength, and sit-to-stand performance, did not differ significantly between groups.

The finding should therefore be interpreted precisely. This is not evidence that L-arginine and vitamin C reverse COPD. Rather, it suggests that part of the fatigue accompanying advanced chronic disease may arise from a systemic vascular and metabolic disturbance that remains modifiable during rehabilitation.

The endothelial nitric oxide axis

The biological rationale for combining L-arginine and vitamin C is compelling.

L-arginine is the substrate for endothelial nitric oxide synthase (eNOS), which generates nitric oxide and contributes to vascular tone, endothelial function, and tissue perfusion. In chronic disease, nitric oxide bioavailability may be reduced through increased arginase activity, endogenous NOS inhibitors such as asymmetric dimethylarginine (ADMA), oxidative stress, and disturbances in L-arginine metabolism.

But providing additional substrate alone may not be sufficient.

Under oxidative conditions, superoxide reacts rapidly with nitric oxide to form peroxynitrite. Oxidation of tetrahydrobiopterin (BH4), an essential eNOS cofactor, favors eNOS uncoupling, shifting the enzyme away from nitric oxide production and toward generation of additional reactive oxygen species.

Vitamin C provides a biologically complementary mechanism. Ascorbate can support nitric oxide bioavailability and BH4-dependent eNOS function by limiting oxidative loss of BH4 and facilitating its recycling.

The combination therefore addresses two components of the same regulatory system: L-arginine provides substrate, while vitamin C may help preserve the biochemical environment required for effective nitric oxide synthesis.

Why fatigue may improve without major changes in performance

Exercise intolerance in advanced COPD is not exclusively pulmonary.

Peripheral endothelial dysfunction, impaired skeletal-muscle perfusion, inflammation, deconditioning, and altered muscle metabolism all contribute to the physiological burden of exertion.

Improving nitric oxide availability could therefore reduce the biological cost of activity without necessarily increasing muscle strength or maximal functional capacity within four weeks.

That interpretation is consistent with the trial. Fatigue improved significantly, whereas objective measures of physical performance did not clearly separate from placebo.

For now, the intervention is therefore better regarded as a microvascular and metabolic adjunct to rehabilitation rather than a performance-enhancing or disease-modifying treatment.

Beyond COPD: a phenotype rather than a diagnosis

The more interesting question is whether this principle extends beyond pulmonary rehabilitation.

The relevant target is probably not COPD itself. It is the biological phenotype characterized by endothelial dysfunction, impaired nitric oxide signaling, oxidative stress, disturbed microvascular recruitment, and peripheral metabolic dysfunction.

That phenotype occurs in multiple chronic diseases.

Long COVID

Here the translational argument already has preliminary clinical support. A randomized placebo-controlled study using the same combination of L-arginine and liposomal vitamin C for 28 days reported improvements in 6-minute walk distance, handgrip strength, flow-mediated dilation, and persistent fatigue in adults with long COVID.

The study was small and does not establish broad efficacy across post-COVID syndromes, but it supports the possibility that the biological effect is not specific to pulmonary parenchymal disease.

Heart failure, peripheral artery disease, and metabolic disease

Heart failure, peripheral artery disease, insulin resistance, and diabetes commonly involve endothelial dysfunction and abnormalities of skeletal-muscle perfusion and metabolism.

These conditions therefore represent biologically plausible settings in which the L-arginine–vitamin C strategy could be tested as an adjunct to structured rehabilitation.

But shared mechanism does not establish shared therapeutic efficacy.

A common pathophysiological pathway provides a rationale for testing an intervention, not permission to assume that the clinical response will be identical across diseases.

The magnitude of intervention should follow the magnitude of biological deviation

There is another important principle.

The presence of endothelial dysfunction does not mean that nitric oxide signaling should simply be driven as strongly as possible.

In physiological systems, the therapeutic objective is not maximal activation. It is restoration toward an appropriate operating range.

This corresponds to what we have described as the Disease Optimality Principle: disease and recovery are dynamic processes in which biological responses may remain appropriate, become insufficient, or become excessive. Successful intervention should therefore depend on the direction and magnitude of deviation from the trajectory appropriate for uncomplicated adaptation and recovery.

Applied here, mild disturbance of endothelial nitric oxide signaling may require little or no pharmacological correction. A larger deviation may justify a stronger intervention. But once the relevant physiological range has been restored, further augmentation provides no necessary biological advantage and may become counterproductive.

This concept may help explain why L-arginine studies have produced heterogeneous results.

Evidence suggests that supplementation is more likely to affect vascular function when baseline endothelial dysfunction, elevated ADMA, or relative impairment of arginine availability is present. In individuals without such disturbance, additional substrate may have little effect.

The treatment target should therefore be the deviation, not the biomarker itself.

Important boundaries

Several findings argue against indiscriminate supplementation.

First, the Thorax trial lasted only 28 days and demonstrated benefit primarily in perceived fatigue. It did not establish long-term disease modification.

Second, L-arginine metabolism is highly context dependent. Increased arginase activity can divert arginine toward ornithine and urea rather than nitric oxide production. In some biological settings, L-citrulline may provide a more efficient route to increasing systemic arginine availability.

Third, evidence from stable chronic disease should not be extended to acute vascular injury. In the VINTAGE MI randomized trial, L-arginine administered after acute myocardial infarction failed to improve vascular stiffness or ventricular function and was associated with excess mortality.

That finding is particularly important conceptually. The same molecule may be useful when it corrects a deficient pathway in one physiological state and inappropriate when introduced into a different biological state.

Therapeutic validity therefore depends not only on what pathway is targeted, but also on when, where, and how far that pathway has deviated from its appropriate physiological range.

The larger lesson

The most interesting aspect of the Thorax study may therefore be broader than L-arginine or COPD.

L-arginine plus vitamin C should not be framed simply as a supplement for pulmonary disease. The combination targets a regulatory system connecting redox state, endothelial nitric oxide signaling, microvascular perfusion, and peripheral metabolism.

The trial suggests that modifying this system can reduce fatigue during pulmonary rehabilitation even when conventional measures of physical performance change little.

Whether the same strategy can improve rehabilitation in other chronic diseases remains an open question.

The appropriate translational approach is therefore not to move from one diagnostic label to another. It is to identify the underlying biological deviation, determine its magnitude and direction, and apply an intervention proportionate to the correction required.

Treat the deviation from physiological optimality, not merely the disease label, and do not correct beyond the range required for uncomplicated adaptation and recovery.

References

1. Maniscalco M, Candia C, Fiorentino G, et al. Targeting fatigue in COPD with chronic respiratory failure undergoing pulmonary rehabilitation: a multicentre, randomised, placebo-controlled trial of L-arginine/liposomal vitamin C. Thorax. Published online September 18, 2026. doi:10.1136/thorax-2026-225106.

2. Tosato M, Calvani R, Picca A, et al. Effects of L-arginine plus vitamin C supplementation on physical performance, endothelial function, and persistent fatigue in adults with long COVID: a single-blind randomized controlled trial. Nutrients. 2022;14. PMID: 36501014.

3. Böger RH. The L-arginine paradox: importance of the L-arginine/asymmetrical dimethylarginine ratio. Pharmacol Ther. 2007. doi:10.1016/j.pharmthera.2007.03.002.

4. Stróżyk S, et al. Endothelial dysfunction due to eNOS uncoupling: molecular mechanisms as potential therapeutic targets. Cell Mol Biol Lett. 2023. PMID: 36890458.

5. Carr AC, Maggini S. Vitamin C and related mechanisms of endothelial nitric oxide regulation. See discussion of ascorbate, tetrahydrobiopterin, and eNOS coupling in the contemporary vitamin C literature. PMID: 33668681.

6. Starikova EA, et al. The mechanisms of L-arginine metabolism disorder in endothelial cells. Biochemistry (Mosc). 2021. doi:10.1134/S0006297921020036.

7. Bai Y, Sun L, Yang T, et al. Association of L-arginine supplementation with markers of endothelial function in patients with cardiovascular or metabolic disorders: a systematic review and meta-analysis. PMID: 30577559.

8. Schulman SP, Becker LC, Kass DA, et al. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA. 2006;295:58-64. doi:10.1001/jama.295.1.58.

More about this topic can be found in our books on Our Books on Google Play and related articles in the Index.

Mykola Iabluchanskyi together with Andriy Yabluchanskiy